Middle-term evolution of patients with advanced cutaneous T-cell lymphoma treated with high-dose recombinant interleukin-2.
Baccard
M
M
Marolleau
J P
JP
Rybojad
M
M
D005500:Follow-Up Studies; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage*; D016410:Lymphoma, T-Cell, Cutaneous / Q000628:therapy*; D012074:Remission Induction; D012878:Skin Neoplasms / Q000628:therapy*
D007376:Interleukin-2